Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Interferon alfa-2a
Drug ID BADD_D01166
Description Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.
Indications and Usage For the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.
Marketing Status Not Available
ATC Code L03AB04
DrugBank ID DB00034
KEGG ID D00745
MeSH ID D000077190
PubChem ID Not Available
TTD Drug ID D0P0WV
NDC Product Code Not Available
Synonyms Interferon alpha-2 | Interferon alpha 2 | Interferon-alpha 2 | Interferon alpha-A | Interferon alpha A | LeIF A | IFN-alpha 2 | IFN-alpha-2 | Interferon alfa-2a | Interferon alfa 2a | Recombinant Interferon alpha-2a | Interferon alpha-2a, Recombinant | Recombinant Interferon alpha 2a | Roferon-A | Roferon A | RoferonA | Ro 22-8181 | Ro 22 8181 | Ro 228181 | Viferon | Sch-30500 | Sch 30500 | Sch30500 | Intron A (Interferon) | Reaferon | Interferon alfa-2b | Interferon alfa 2b | Interferon alpha-2b, Recombinant | Interferon alpha 2b, Recombinant | Recombinant Interferon alpha-2b | Recombinant Interferon alpha 2b | IFNalpha-2b, Recombinant | IFNalpha 2b, Recombinant | Recombinant IFNalpha-2b
Chemical Information
Molecular Formula Not Available
CAS Registry Number 76543-88-9
SMILES Not Available
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rhinorrhoea22.02.05.010--
Salivary hypersecretion07.06.01.009--Not Available
Sarcoidosis10.02.06.001--Not Available
Seborrhoea23.02.07.001--Not Available
Sedation17.02.04.005--Not Available
Seizure17.12.03.001--
Sinusitis22.07.03.007; 11.01.13.005--
Sleep disorder19.02.04.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Stomatitis07.05.06.005--
Suicidal ideation19.12.01.003--
Suicide attempt19.12.01.004--
Syncope24.06.02.012; 17.02.04.008; 02.01.02.008--
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Tachypnoea22.02.01.014--Not Available
Throat irritation22.02.05.013; 07.05.03.004--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombophlebitis24.01.02.001--Not Available
Transient ischaemic attack24.04.06.005; 17.08.04.001--
Urticaria23.04.02.001; 10.01.06.001--
Vasculitis24.05.02.001; 10.02.02.006--
Vertigo04.04.01.003; 17.02.12.002--
Visual acuity reduced17.17.01.011; 06.02.03.001--
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Mental status changes19.07.01.001--Not Available
Hypoacusis04.02.01.006--
Contusion23.03.11.002; 15.03.01.008; 12.01.06.001; 24.07.06.001--
Respiratory tract congestion22.02.07.003--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages